CLOSED
GET A PIECE OF REFLEX
The Five-Second Neurological Vital
Show more
REASONS TO INVEST
TEAM
Kurtis William Sluss • CEO & Director
Read More
Michael Heims • CFO & Director
Read More
*Market information provided by (source) (source) (source) (source)
overview
Leveraging Machine Learning and Mobile Tech to Support The Clinical Diagnostic Process
Offering cutting-edge patented technology in an accessible and cost-effective format, Reflex’s testing suite can be used to easily capture neurological vitals. This is critical to diagnosing concussions and a multitude of other medical conditions. Reflex Pro works by integrating with mobile phone or tablet processors to measure the pupillary light reflex and provide actionable metrics that support the diagnostic process. To the best of our knowledge, Reflex Pro is the only clinically validated tool of its kind, collecting anonymized data en masse for a common database, and using it to continually optimize product capabilities.
the problem & our solution
Providing Real-Time Diagnostic Data for Modern Medical Professionals
Within the medical community, functional neurologists are collectively tasked with 71M patient visits each year – encompassing a $360B industry – but they are largely operating without access to objective neurological vitals (source). These clinicians are often the first to diagnose and treat concussions among other neurological disorders, but the lack of rapid testing and quantitative data makes it difficult to give patients accurate assessments of their injury and recovery status.
To solve this systemic need, Reflex has developed a patented 5-second neurological vital testing suite that allows practitioners to instantly access meaningful neurological metrics. Reflex Pro is easy to implement within any medical practice via a simple tiered subscription model for unlimited testing. In independent clinical studies our system has been proven effective as a biomarker of concussion (source), scoring higher than all other adjacent technologies evaluated (source). Meanwhile, additional research demonstrates that it may be a valuable asset in other diagnostic capacities, such as assessing opiate withdrawal, autism, and Parkinson's.
the market & our traction
A Proven Business Model Supported By Sound Concussion Science
According to a recent FDA survey, the average cost to bring a middle-regulated, pre-revenue product to market is $31M (source), yet the Reflex team has been able to build, launch, and scale Reflex through its early adoption phase, as a medical device, with a starting investment of just over $900K.
Milestones reached within our first two years as a company includes over 210 clinics and 30K patients served, with a customer retention rate of 96% and 90% gross revenue growth in 2021. The company has been able to secure patent protection for its ability to carry out testing on all mobile devices. Additionally, our company has a standing license for all of our direct competitor's pupillometer patents. Reflex's model includes proprietary machine learning technology for efficient, low-error processing.
Most excitingly, Reflex Pro has achieved proof-positive status through third-party clinical studies. The technology was featured in the largest neuro-pupillometric study ever conducted in 2021, with a patient population of over 20K (source), and was selected for a Department of Defense study in a 2-year concussion management study after receiving the institution's highest evaluation score (source).
why invest
Enlightening Medical Professionals On a Global Scale
For centuries, doctors have understood the connection between the pupils and neurological health (source), yet it’s taken hundreds of years for innovation to catch up and provide the proper support tools. Having developed a tech-enhanced solution that we hope will serve over 5 million physicians, nurses, athletic trainers, physical therapists, and chiropractors worldwide, Reflex is seeking to lead the way and ready to embark on our path to expansion. Our ten-year vision entails scaling our sales and staff, finalizing Class II clinical clearance with an indication for concussion, and positioning the technology as an industry standard. Help us realize our mission by investing today!
ABOUT
HEADQUARTERS
1230 Hoyt Ave
Indianapolis, IN 46032
WEBSITE
View Site
TERMS
Reflex
Overview
PRICE PER SHARE
$2.37
DEADLINE
Feb. 7, 2023 at 7:59 AM UTC
VALUATION
$15.48M
FUNDING GOAL
$15K - $1.23M
Breakdown
MIN INVESTMENT
$244.11
MAX INVESTMENT
$1,234,997.52
MIN NUMBER OF SHARES OFFERED
6,329
MAX NUMBER OF SHARES OFFERED
521,096
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives & Bonuses*
Time-Based:
First 72 Hours - 15% Bonus Shares
Next 72 Hours - 10% Bonus Shares
Next 7 Days - 5% Bonus Shares
Amount-Based:
$1,000 | Tier 1
$1,000 or more and receive a year of access to Reflex Pro with Reflex Telehealth for free. This offer is only available to qualified medical professionals and validated by the Reflex Team.
$5,000 | Tier 2
5% Bonus Shares
$10,000 | Tier 3
10% Bonus Shares
$20,000 | Tier 4
20% Bonus Shares
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Brightlamp, Inc. (dba "Reflex") will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.37 / share, you will receive 110 Common Stock shares, meaning you'll own 110 shares for $237. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
ALL UPDATES
02.06.23
0 Days Left, Last Chance to Invest! Thank You For Your Support. 😊
It's been fun and thank you to everyone who has supported us. Reflex is a technology that deserves everyone's input and we're glad we were able to provide this opportunity to the general public. Cheers!
02.05.23
1 Day Remains; This Is It. Invest Today.
02.04.23
2 Days to Go. Once It's Gone, It's Gone!
02.03.23
Only a Few Days Left to Invest in the Brain Checker! 💆♀️🧠
02.02.23
What Your Investment Really Buys: A Letter From the CEO 📬
Dear Investor,
First, thank you for your consideration and taking the time to read this brief note. Our team greatly appreciates the community we've been able to build on StartEngine whether you're a watcher, interested party, browser, or current investor, we're glad you're here.
Reflex over the years has become something much more than a clinical tool. It's sending a message to the market that digital medical devices can break the mold of dermatological mole checkers or heart rate monitors. We've made, tested, sold, and grown something that pushes the limits of what we thought a medical device "is". Reflex truly sets the precedence for what a software as a medical device (SaaMD) should aim to be. Thankfully, we have more work to do in exercising this precedence and to help more people.
"What does my investment buy me?", is one of my favorite questions I've been asked. Some say objectives (e.g. 1,000 number of users). Some say runway (e.g. two years). And many don't really even have an answer. Hell, some even blurt out "Shares!", but I digress.
My preference is to be explicit when addressing this line of questioning. Users, runway, shares, etc. are all things that come with investment but it isn't what your investment buys.
Your investment buys action.
It purchases accessible neuro-healthcare for many that would ultimately struggle to obtain.
Investment in Reflex buys progress towards better outcomes for at least one patient that truly needs it.
These are the most important tenants of how and why we operate. If this attitude aligns with your interests then we would love to have you along for the ride. Invest today to help make a difference tomorrow.
Cheers,
Kurtis Sluss, CEO
Reflex | reflexapp.io
02.01.23
Only 5 Days Left. Can I answer your questions about Reflex? 🙋♀️🙋🙋♂️
Any questions I can answer regarding investing in Reflex in these last five days?
We've been active in the chat on StartEngine and strive to answer questions within just a couple of hours. Drop us any questions you may have over the next 5 days and we'll be sure to answer them! Here are some common questions we typically get?
- Q: How accurate is Reflex? A: Since Reflex is a regressive tool we tend to think about it as an error rate. Reflex touts a less than 3% mean absolute error as compared to real annotated datasets our team has rigorously vetted.
- Q: Who can use Reflex? A: All medical professionals who see value in obtaining neurological data for patient vitals and monitoring. It's clear that nearly all medical professionals can benefit from Reflex even though we target a few key audiences as part of our go-to-market strategy.
- Q: How much does it cost? We're a fraction of the cost of our direct competitors that use capital equipment to service the market. Priced at $400/yr starting, all users can feel economic relief using Reflex. P.S. that's for unlimited testing AND there's no single use plastics!
01.27.23
Don't Sleep on This Opportunity. 10 Days to Go. 😴💤
01.24.23
Under 14 Days Remain: Be Part of the Next Wave in Medicine. 🌊 🏥
Help Us Help People with Neurological Challenges: Invest Today.
Our mission is bigger than just an investment. We deploy your investment specifically to help others get the neurological attention they deserve. Check it out below:
01.20.23
📢 Reflex Featured in Kaiser Health News: Check it Out!
Reflex Featured as Leader in Neurological Medical Apps
Read the rest of the article here: https://khn.org/news/article/smartphone-health-data-diagnostic-tool/
"Brightlamp’s Reflex app is a clinical decision support tool for helping manage concussions and vision rehabilitation, among other things. Using an iPad’s or iPhone’s camera, the mobile app measures how a person’s pupils react to changes in light. Through machine learning analysis, the imagery gives practitioners data points for evaluating patients. Brightlamp sells directly to health care providers and is being used in more than 230 clinics. Clinicians pay a $400 standard annual fee per account, which is currently not covered by insurance. The Department of Defense has an ongoing clinical trial using Reflex."
01.19.23
NEW: mTBI Results Confirmed for Pediatric Population w/ Reflex 💣
Discovered, Confirmed, Re-Confirmed - Reflex & mTBI
Following a seminal paper in 2021 featuring Reflex, SPARCC confirmed results in the pediatric population for mild traumatic brain injury (mTBI, otherwise known as concussion).
REWARDS
10%
Stack Venture Club & Rewards!
Members get an extra 10% shares in addition to rewards below!
Venture Club
Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
$1,000
$1,000 | Tier 1
$1,000 or more and receive a year of access to Reflex Pro with Reflex Telehealth for free. This offer is only available to qualified medical professionals and validated by the Reflex Team.
$5,000
$5,000 | Tier 2
5% Bonus Shares
$10,000
$10,000 | Tier 3
10% Bonus Shares
$20,000
$20,000 | Tier 4
20% Bonus Shares
JOIN THE DISCUSSION
0/2500
Richard Koch
2 years ago
Thanks -- all good stuff!
1
0
Richard Koch
2 years ago
Could the software be tweaked to detect impaired drivers? That could be an entirely new product line.
1
0
Latoya Freeman
3 years ago
Hello, does this product need FDA approval/clearance to be used as "SaaMD" and if so, do you have it?
Show more
1
0
Ajith Potluri
3 years ago
Hello team Please explain the investors what exactly you are going to diagnose or rule out some of the serious neurological conditions by using your product. How much it cost to the clinician individually or for a multi provider clinic to have access to your product. for early investors, what are the exit options and how long (3, 5 or 7 years. Are you aware another app Hitcheck used to evaluate concussion in persons with on field sports injuries. Now in use by several big sports teams. Thank you
Show more
2
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Richard Koch
2 years ago
Kurtis, Please address the absence of any reference to Android. Are potential users limited to Apple? If so, please help me understand why Android users would be blocked from your products. Do you have plans to include Android users in this or any potential future product?
Show more
2
0